The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

• Status: Completed
• Trial end date: 2019-12-15
• Target enrollment: 0
• Participant gender: All

Summary

Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ohio State University
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

1. Subjects undergoing outpatient surgeries (laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy) under general anesthesia requiring rocuronium-induced neuromuscular blockade

2. Male or female patient 18 years and older

3. Able to consent

4. American Society of Anesthesiologist (ASA) physical status of I, II, or III

Exclusion Criteria:

1. Participating in another interventional study drug within 30 days prior to their recruitment

2. Special population (Pregnant, Inmate, Breastfeeding)

3. History of allergy to sugammadex or rocuronium

4. Any medication known to interfere with NMBA or sugammadex

5. Presence of any clinical condition as determined by the investigator that exclude the patient from the trial such as COPD, CKD, and neuromuscular or neurodegenerative diseases